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Membranous nephropathy is an immune kidney disease caused by IgG antibodies
that form glomerular subepithelial immune complexes. Proteinuria is mediated by
complement activation, as a result of podocyte injury by C5b-9, but the role of specific
complement pathways is not known. Autoantibodies-mediating primary membranous
nephropathy are predominantly of IgG4 subclass, which cannot activate the classical
pathway. Histologic evidence from kidney biopsies suggests that the lectin and the
alternative pathways may be activated in membranous nephropathy, but the pathogenic
relevance of these pathways remains unclear. In this study, we evaluated the role of
the alternative pathway in a mouse model of membranous nephropathy. After inducing
the formation of subepithelial immune complexes, we found similar glomerular IgG
deposition in wild-type mice and in factor B-null mice, which lack a functional alternative
pathway. Unlike wild-type mice, mice lacking factor B did not develop albuminuria nor
exhibit glomerular deposition of C3c and C5b-9. Albuminuria was also reduced but not
completely abolished in C5-deficient mice. Our results provide the first direct evidence
that the alternative pathway is necessary for pathogenic complement activation by glomerular subepithelial immune complexes and is, therefore, a key mediator of proteinuria
in experimental membranous nephropathy. This knowledge is important for the rational
design of new therapies for membranous nephropathy.
Keywords: membranous nephropathy, glomerulonephritis, albuminuria, alternative pathway, membrane attack
complex, factor B, complement C5, mouse models

INTRODUCTION
Membranous nephropathy (MN), one of the leading causes of nephrotic syndrome in adults, is an
antibody-mediated kidney disease clinically characterized by proteinuria, often heavy and persistent.
MN is a disease of heterogeneous etiology, defined histologically by immune complexes deposited
on the subepithelial side of glomerular basement membrane (GBM), together with GBM thickening
Abbreviations: AP, alternative pathway; GBM, glomerular basement membrane; MN, membranous nephropathy; PLA2R,
phospholipase A2 receptor; THSD7A, thrombospondin type-1 domain-containing 7A.
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factor B (an essential component of the AP), we found that the
absence of a functional AP prevented complement activation by
subepithelial immune complexes (as assessed from the glomerular deposition of C3c and C5b-9) and abolished proteinuria.
These findings provide the first direct evidence implicating the
AP activation in the pathogenesis of MN. This knowledge may
provide a framework for developing new therapeutic strategies
for MN.

and podocyte foot process effacement, but little glomerular
inflammation. The most prevalent form is primary MN, now
understood as an autoimmune disease in which IgG autoantibodies (predominantly of IgG4 subclass) form subepithelial immune
complexes with autoantigens expressed on podocyte cell surface
(1, 2). About 70% of patients with primary MN have autoantibodies targeting phospholipase A2 receptor (PLA2R), and an
additional 3–5% have autoantibodies targeting thrombospondin
type-1 domain-containing 7A (THSD7A) (3, 4). Secondary MN
can occur when circulating antibodies bind to antigens planted
in the subepithelial space, such as cationic bovine serum albumin
of dietary origin (5).
In the current paradigm for the pathogenesis of MN, complement activation is a major effector mechanism of subepithelial
immune complexes (1, 6). Complement activation is initiated by
three canonical pathways. The classical pathway is triggered by
immune complexes and the lectin pathway—by certain danger
patterns, while the alternative pathway (AP) is constitutively
active and self-amplifies on foreign surfaces. The AP also amplifies activation that is initiated through the other two pathways.
All three pathways converge toward the assembly of C3 and C5
convertases, which generate pro-inflammatory anaphylatoxins
(C3a, C5a), opsonins that mediate immune adhesion (C3b, iC3b),
and the membrane attack complex (C5b-9), which lyses cells.
In human MN, C3 fragments and C5b-9 are present alongside
IgG in subepithelial deposits, while urinary excretion of sC5b-9
associates with immune disease activity (7–9). Studies in passive
Heymann nephritis, a faithful rat model of MN, have specifically
implicated C5b-9 as a key mediator of podocyte injury and
proteinuria (10, 11). However, the role of different complement
pathways upstream of C5 activation in human and experimental
MN remains largely unknown.
How immune complexes activate complement in MN remains
a conundrum because the autoantibodies implicated in primary
MN are predominantly of IgG4 subclass (6, 12–14). Although
immune complexes typically bind C1q and activate the classical pathway, IgG4 does not bind C1q and is considered unable
to activate complement—at least not via the classical pathway
(15–17). In kidney biopsies from patients with primary MN,
glomerular staining for C1q is almost always weak or absent,
while staining for mannan-binding lectin (MBL) and C4d is
usually positive (except in patients with MBL deficiency), consistent with the activation of the lectin pathway (18–20). Beck
and Salant proposed that the lectin pathway may be activated
by IgG4 glycoforms that lack terminal galactose and sialic acid,
and, therefore, can bind MBL (1, 6). However, the occurrence
of primary MN in patients with MBL deficiency shows that the
lectin pathway is not absolutely required (21). Glomerular deposition of properdin and factor B—which is indicative of the AP
activation—is also common in MN (18, 21), but the pathogenic
relevance of this pathway is not known.
The goal of this study was to determine the contribution of
the AP to glomerular injury and proteinuria mediated by subepithelial immune complexes. For this purpose, we used a mouse
model that recapitulates clinical and morphologic features of
human MN (22–25) and which was found to exhibit proteinuria
exacerbated by C5 activation. Using Cfb−/− mice, which lack
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MATERIALS AND METHODS
Materials

The recombinant non-collagenous (NC1) domain of human
α3(IV) collagen (rh-α3NC1) was expressed in HEK293 cells and
purified as described (26).

Animal Experiments

DBA/1J (D1), DBA/2J (D2), and C57Bl/6J (B6) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA).
Breeding pairs of Cfb−/− mice backcrossed on the B6 background
for more than nine generations (B6.Cfb−/−) were obtained from
Dr. Joshua Thurman and maintained by homozygous breeding. D1.Cfb−/− mice were generated by backcrossing onto the
D1 background for four generations and then intercrossing F4
heterozygous mice. Mice were housed in a specific pathogen-free
facility with free access to food and water. The study was carried
out in accordance with the recommendations of the National
Institutes of Health Guide for Care and Use of Laboratory
Animals and the protocol was approved by the local Institutional
Animal Care and Use Committee.
To induce experimental membranous nephropathy, mice
(6–10 weeks old, both male and female) were immunized subcutaneously at two sites on the back with rh-α3NC1 antigen (30 µg
in 50 µL sterile phosphate-buffered saline) emulsified in an equal
volume of Complete Freund’s Adjuvant (Sigma, St. Louis, MO,
USA). D1 and D2 mice received one booster immunization with
the rh-α3NC1 antigen in Incomplete Freund’s Adjuvant (Sigma,
St. Louis, MO, USA) on day 21 after the first immunization. B6
mice were boosted four times with rh-α3NC1 in Incomplete
Freund’s Adjuvant, at 10 days interval starting on day 14 after the
first immunization. As negative controls, some mice were immunized with adjuvant alone in each experiment. Unless otherwise
indicated, mice were euthanized at 8 weeks (for D1 and D2 mice)
or 12 weeks (for B6 mice) after the initial immunization, and
tissues and blood were collected for further evaluations.

Evaluation of Kidney Function

Spontaneously voided spot urine samples were collected by
placing mice over 96-well microtiter plates and then analyzed
as follows. Urinary albumin was measured by capture ELISA
using a mouse albumin quantitation kit (Bethyl, Montgomery,
TX, USA). Urine creatinine and blood urea nitrogen levels
were measured using Infinity creatinine and urea liquid stable
reagents (Thermo Fisher Scientific, Middletown, VA, USA),
according to the manufacturer’s protocols. To account for urine
tonicity, albuminuria was expressed as urinary albumin-tocreatinine ratio (ACR).

2

June 2018 | Volume 9 | Article 1433

Luo et al.

Alternative Pathway Mediates Membranous Nephropathy

Evaluation of Mouse IgG Autoantibody
Production

All sections from one experiment were stained and analyzed at
the same time.

Sera were assayed for the presence of IgG antibodies to rh-α3NC1
by ELISA. Briefly, 96-well microtiter plates (Nunc MaxiSorp) were
coated overnight with rh-α3NC1 (100 ng per well) in carbonatebicarbonate buffer, pH 9.6. After blocking with 1% bovine serum
albumin, the wells were incubated for 1 h with mouse sera diluted
1/5,000 for detection of total IgG, 1/2,000 for detection of IgG1,
or 1/500 for detection of IgG2a and IgG2b. Secondary antibodies were alkaline phosphatase-conjugated goat anti-mouse IgG
(Rockland Immunochemicals, Gilbertsville, PA, USA) and
horseradish peroxidase-conjugated goat anti-mouse IgG1, IgG2a,
IgG2b, or IgG2c (Bethyl, Montgomery, TX, USA). Plates were
developed with p-nitrophenol phosphate or tetramethylbenzidine
(Sigma, St. Louis, MO, USA) as substrate, and absorbance was
read at 405 nm with a SpectraMax ELISA plate reader (Molecular
Devices, Sunnyvale, CA, USA).

In Vitro Complement Activation

Fresh frozen normal mouse serum, collected from DBA/1 mice,
and stored in aliquots at −70°C, was used as a source of complement. Cryosections of mouse kidneys fixed in cold acetone were
incubated overnight at 37°C with normal mouse serum diluted 1:3
in veronal buffered saline (Sigma, St. Louis, MO, USA) containing
0.1% Tween 20 and supplemented with: (a) 2.5 mM calcium chloride and 0.7 mM magnesium chloride; or (b) 2.5 mM magnesium
chloride and 6.2 mM EGTA; or (c) 25 mM EDTA. Complement
activation was visualized by staining with FITC-conjugated goat
anti-mouse C3c, as described above.

Statistical Analyses

Analyses were performed using GraphPad Prism 7.00 software
(San Diego, CA, USA). ACRs were log transformed. The significance of differences was determined by unpaired t test or by oneway analysis of variance (ANOVA) with Dunnett’s correction
for multiple comparisons. A value of P < 0.05 was considered
statistically significant. Values are presented as means ± SEM.

Renal Histopathology and
Immunofluorescence Microscopy

For light microscopy, portions of mouse kidneys were fixed in
10% buffered formalin, dehydrated through a graded ethanol
series, and embedded in paraffin. Paraffin sections (2 µm thick)
were stained with periodic-acid Schiff reagent. Transmission
electron microscopy was performed as described (27). For
immunofluorescence, portions of mouse kidneys embedded
in OCT were snap-frozen in isopentane and stored at −70°C.
Cryosections cut at a thickness of 5 µm were fixed in cold
acetone for 10 min. Mouse IgG was visualized using FITCconjugated goat anti-mouse IgG (BD Bioscience Pharmingen,
San Jose, CA, USA). Complement C3 was visualized using FITCconjugated goat anti-mouse C3c (Nordic Immunology, Tilburg,
Netherlands). Kidney deposition of rh-α3NC1 was visualized
with rat IgG mAb RH34 (a gift from Dr. Yoshikazu Sado, Shigei
Medical Research Institute, Japan), which is specific for human
but not mouse α3NC1 (28). Mouse C5b-9, properdin, factor
H, and C4 were visualized using rabbit anti-C5b9 (Abcam;
Cambridge, MA, USA), rabbit anti-properdin (Santa Cruz, CA,
USA), rat IgG anti-mouse C4d mAb (HyCult, Netherlands), and
rat IgG anti-mouse factor H mAb (MAB4999, R&D Systems,
Minneapolis, MN, USA). Nephrin was visualized using guinea
pig anti-nephrin (Progen, Germany). Heparan sulfate chains
were visualized with mouse IgM mAb JM403 (29). Agrin was
visualized using a rabbit anti-agrin polyclonal antibody (kindly
provided by Dr. Takako Sasaki, Oita University, Japan), as
previously described (27). Secondary antibodies were Alexa
Fluor 488-conjugated goat anti-rabbit IgG, goat anti-rat IgG,
donkey anti-guinea pig IgG, goat anti-mouse IgM (Invitrogen,
Carlsbad, CA, USA), and FITC-goat anti-rat IgG (BD Bioscience
Pharmingen, San Jose, CA, USA). Sections were mounted with
anti-fade reagent (Invitrogen, Carlsbad, CA, USA), then coverslipped and observed using a fluorescence microscope (Nikon
Eclipse E800). Photomicrographs were captured with a digital
camera attached to the microscope, using the same exposure
settings for each primary antibody. For quantitative analyses,
images were analyzed with Image J software, as described (30).
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RESULTS
Complement C5 Deficiency Ameliorates
Albuminuria Induced by Subepithelial
Immune Complexes in Mice Immunized
With α3NC1

DBA/1 (D1) mice immunized with α3NC1 develop kidney disease recapitulating clinical and morphologic features of human
MN (22–25). This model exhibits proteinuria associated with
subepithelial immune complexes and glomerular deposition of
IgG, C3, and C5b-9, but the role of complement activation in
proteinuria is not known. We reasoned that if C5b-9 is pathogenic
in this mouse model (analogous to the rat Heymann nephritis
model), then, proteinuria would be ameliorated by the genetic
deficiency of complement C5, which occurs naturally in several
inbred strains of mice (31). To test this conjecture, we induced
experimental MN in C5-deficient DBA/2 (D2) mice, which are
nearly 95% genetically identical to C5-sufficient D1 mice (32).
Compared to D1 mice, D2 mice immunized with α3NC1
developed much milder albuminuria (Figure 1A). At week 8
after the first immunization, the endpoint for this experiment,
the urine ACR in α3NC1-immunized D2 mice (2.4 ± 0.96) was
significantly lower (P < 0.001) than that in α3NC1-immunized
D1 mice (77.1 ± 20.8), albeit greater than in control D2 mice
immunized with adjuvant alone (ACR 0.16 ± 0.07) (Figure 1B).
Blood urea nitrogen levels did not increase over the baseline
(mean values at week 0 and at week 8 were 23.1 and 20.3 mg/dL
for D1 mice, 27.8 and 25.4 mg/dL for D2 mice), indicating that
the renal function did not decline during the duration of the
experiment. Serum levels of mouse IgG anti-α3NC1 antibodies
were similar in D1 and D2 mice (data not shown). Kidneys were
collected at 8 weeks post-immunization for morphologic evaluation. By light microscopy, kidneys from α3NC1-immunized mice
3
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Figure 2 | Analysis of glomerular immune complexes and complement
deposition in D1 and D2 mice immunized with α3NC1. Kidneys were
collected at week 8 post-immunization from adjuvant immunized D2 mice
(left), α3NC1-immunized D2 mice (middle), and α3NC1-immunized D1 mice
(right). (A) Direct immunofluorescence staining shows mouse IgG binding
along the glomerular basement membrane (GBM) in α3NC1-immunized D1
and D2 mice. Control mice show non-specific mesangial deposition of
mouse IgG. (B) Mean fluorescence intensity (MFI) of IgG staining, expressed
in arbitrary units (AU), was compared in α3NC1-immunized D2 and D1 mice.
The difference was not significant (n.s.) by t test. (C) Indirect
immunofluorescence staining with mAb RH34 shows GBM deposition of
exogenous antigen in all α3NC1-immunized mice, which is absent in
adjuvant-immunized mice. (D) Direct immunofluorescence staining reveals
C3c deposition along the capillary loops in α3NC1-immunized D1 and D2
mice. In control mice, C3c staining is positive in the Bowman’s capsule and
kidney tubules. (E) Indirect immunofluorescence shows capillary loop staining
for C5b-9 in α3NC1-immunized D1 mice. A weak background of non-specific
immunofluorescence is observed in adjuvant-immunized and α3NC1immunized D2 mice. Original magnification 400×.

Figure 1 | C5 deficiency protects against albuminuria in experimental MN.
(A) Time course of urinary albumin-to-creatinine ratio (ACR) in D1 mice
(circles) and D2 mice (squares) immunized with α3NC1 (N = 5–7 per group).
Control D2 mice (triangles) were immunized with adjuvant alone (N = 3).
Shown are means and SEM. (B) Scatterplot depicting the final ACR values
(at week 8). The significance of differences among groups was analyzed by
one-way ANOVA with Dunnett’s correction for multiple comparisons.
***P < 0.001, ****P < 0.0001. n.s., not significant. (C) Light microscopy
shows normal appearance of glomeruli and tubules in α3NC1-immunized D2
and D1 mice (periodic acid–Schiff staining; original magnification 400×). (D)
Transmission electron microscopy shows subepithelial electron dense
deposits (arrowhead), areas of glomerular basement membrane (G)
thickening, and effacement of podocyte (Po) foot processes. Original
magnification 7,500×.

appeared relatively normal, with little glomerular inflammation
(Figure 1C); however, electron microscopy revealed areas of
thickened GBM surrounding subepithelial deposits and podocyte
foot process effacement (Figure 1D).
Immunofluorescence microscopy showed mouse IgG staining
along the GBM in all α3NC1-immunized mice (Figure 2A). The
IgG staining intensity was similar in D1 and D2 mice (Figure 2B).
Staining with an antibody that binds to human but not mouse
α3NC1 (mAb RH34) showed capillary loop deposition of
exogenous antigen in α3NC1-immunized but not control mice
Frontiers in Immunology | www.frontiersin.org

(Figure 2C). GBM staining for C3c, which indicates recent complement activation, was also found in all α3NC1-immunized
mice (Figure 2D). However, glomerular deposition of C5b-9
was only found in α3NC1-immunized D1 mice (Figure 2E), as
expected based on the C5 deficiency in D2 mice. A decrease
in nephrin staining in α3NC1-immunized D1 mice compared
to D2 mice confirmed an injured podocyte phenotype (not
shown). These results imply that C5 activation exacerbates
proteinuria induced by subepithelial immune complexes in

4
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of albuminuria induced by α3NC1 immunization in B6.Cfb−/−
mice to congenic wild-type B6 mice (B6.Cfb+/+) (Figure 4A).
At the endpoint in this experiment (i.e., at 12 weeks after the
initial immunization), the urinary ACR in α3NC1-immunized
B6.Cfb−/− mice (0.11 ± 0.05) was similar to that in adjuvantimmunized B6 mice (0.057 ± 0.011); both were significantly
lower (P < 0.0001) than the urine ACR in α3NC1-immunized
B6.Cfb+/+ mice (10.6 ± 5.9) (Figure 4B). Two mice from each
group were observed for an additional 4 weeks; albuminuria
further increased in Cfb+/+ mice but not in Cfb−/− mice. In both
groups of α3NC1-immunized B6 mice, kidney morphology mice
appeared relatively normal by light microscopy (Figure 4C).

α3NC1-immunized mice, presumably as a result of podocyte
injury by C5b-9.

Evidence of the AP Activation by
Subepithelial Immune Complexes

To determine which complement pathways may be activated by
subepithelial immune complexes, we assessed glomerular deposition of properdin, factor H, and C4d. Properdin and factor H
are positive and negative regulators of the AP, respectively, while
C4d is a marker of the classical and lectin pathway activation.
Capillary loop staining for both properdin (Figure 3A) and factor
H (Figure 3B) was found in α3NC1-immunized D1 mice but not
in control mice. All mice had staining for C4d in a non-specific
mesangial pattern (Figure 3C), also commonly seen in normal
human glomeruli (33). In addition, α3NC1-immunized mice
also had segmental staining for C4d along the capillary loops,
suggesting that subepithelial immune complexes formed in these
mice activate multiple complement pathways, similar to what is
observed in human MN (18). While these results are indicative
of the AP activation, the pathogenic relevance of the AP cannot
be inferred from morphologic findings alone.

B6.Cfb−/− Mice Immunized With α3NC1
Develop Subepithelial Immune Complexes
but Are Protected Against Albuminuria
and Do Not Exhibit Glomerular
Complement Deposition

The absence of a functional AP in Cfb−/− mice afforded a strategy
to investigate the role of the AP in experimental MN. We initially
obtained Cfb−/− mice backcrossed on the B6 background for nine
generations (B6.Cfb−/−), which allowed us to compare the course

Figure 4 | B6.Cfb−/− mice immunized with α3NC1 are protected against
albuminuria despite developing subepithelial immune complexes. (A) Time
course of urinary albumin-to-creatinine ratio (ACR) in B6.Cfb+/+ mice (circles)
and B6.Cfb−/− mice (squares) immunized with α3NC1 (N = 7 per group).
Control B6 mice (triangles), including both genotypes, were immunized with
adjuvant alone (N = 7). Shown are means and SEM. (B) Scatterplot depicts
the ACR values at the endpoint of this experiment (week 12). The significance
of differences among groups was analyzed by one-way ANOVA with
Dunnett’s correction for multiple comparisons. ***P < 0.001, ****P < 0.0001.
n.s., not significant. (C) Morphology of kidneys from α3NC1-immunized
B6.Cfb−/− and B6.Cfb+/+ mice appears normal by light microscopy (periodic
acid–Schiff staining, original magnification 400×). (D) Transmission electron
microscopy shows subepithelial electron dense deposits (arrowhead),
expansion of the glomerular basement membrane (G), and podocyte (Po)
foot process effacement. Original magnification 7,500×.

Figure 3 | Histologic evidence of AP activation in experimental MN.
Glomerular deposition of properdin (A), factor H (B), and C4d (C) was
evaluated by indirect immunofluorescence staining of frozen kidney sections
from α3NC1-immunized D1 mice and adjuvant-immunized control mice.
Properdin and factor H staining along the capillary loops was found in
α3NC1-immunized D1 mice, but not in adjuvant-immunized mice. Mesangial
C4d staining was found in all mice, while weaker segmental staining for C4d
along capillary loops was also present in α3NC1-immunized mice.

Frontiers in Immunology | www.frontiersin.org
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Electron microscopy showed features of MN including subepithelial deposits, GBM expansion, and foot process effacement
(Figure 4D).
Humoral immune responses to α3NC1 were comparable in
immunized B6.Cfb−/− and B6.Cfb+/+ mice, as shown by similar levels
of circulating mouse IgG, IgG1, IgG2b, and IgG2c anti-α3NC1 antibodies (Figure 5). Immune complexes and complement deposition
were evaluated by immunofluorescence microscopy (Figure 6).
GBM staining for mouse IgG was found in all α3NC1-immunized
mice (Figure 6A), with similar intensity in B6.Cfb−/− and B6.Cfb+/+
mice (Figure 6B). GBM deposition of exogenous antigen in
α3NC1-immunized mice was indicated by positive staining with
mAb RH34 (Figure 6C). Deposition of C3c along the GBM was
found in α3NC1-immunized Cfb+/+ mice but was completely
absent in immunized Cfb−/− mice (Figure 6D); as also found for
C5b-9 (Figure 6E). These results indicate that the absence of factor
B does not affect the formation of subepithelial immune complexes
but prevents glomerular complement activation and abolishes
proteinuria induced by immunization with α3NC1.

D1.Cfb−/− mice were resistant to development of albuminuria induced by α3NC1 immunization (Figure 7A). At the
final time point (at week 8 post-immunization), urine ACR in
α3NC1-immunized D1.Cfb−/− mice (0.36 ± 0.12) was similar
to that in adjuvant-immunized D1 mice (0.078 ± 0.023);
both were significantly lower (P < 0.0001) than urine ACR in
α3NC1-immunized D1.Cfb+/+ mice (78.8 ± 18.1) (Figure 7B).
Morphologic analyses of the kidneys collected at week 8 largely
recapitulated the findings from B6 mice. Light microscopy did
not show major glomerular abnormalities (Figure 7C), while
electron microscopy showed subepithelial deposits with GBM
thickening and effaced podocyte foot processes (Figure 7D).
GBM staining for mouse IgG was found in all α3NC1immunized but not control mice (Figure 8A). The IgG

Absence of Proteinuria and Glomerular
Complement Deposition in D1.Cfb−/− Mice
Immunized With α3NC1 Corroborates
the Pathogenic Role of the AP in
Experimental MN

We sought to verify whether the ablation of the AP also prevents
albuminuria in D1 mice, which are more susceptible to MN.
Results in B6 mice cannot be directly compared to those in D1
and D2 mice because B6 mice are more resistant to experimental
kidney disease and develop milder proteinuria requiring repeated
immunizations with α3NC1. After backcrossing to D1 for four
generations, we generated D1.Cfb−/− mice, which had about
94% D1 genetic background (comparable to almost 95% genetic
similarity between D1 and D2 mice).

Figure 6 | Analysis of glomerular immune complexes and complement
deposition in B6 mice immunized with α3NC1. Kidneys from adjuvantimmunized B6 mice (left), α3NC1-immunized B6.Cfb−/− mice (middle), and
α3NC1-immunized B6.Cfb−/− mice (right) were collected at week 12 after the
initial immunization. (A) Immunofluorescence staining for mouse IgG shows
glomerular basement membrane (GBM) staining in α3NC1-immunized
B6.Cfb−/− and B6.Cfb+/+ mice. Adjuvant-immunized mice show non-specific
mesangial IgG deposition. (B) Mean fluorescence intensity (MFI) of IgG
staining, expressed in arbitrary units (AU), was compared in α3NC1immunized B6.Cfb−/− and B6.Cfb+/+ mice. Significance was evaluated by t
test (n.s., not significant). (C) Staining with mAb RH34 shows GBM
deposition of exogenous antigen in α3NC1 immunized B6.Cfb−/− and B6.
Cfb+/+ mice, which is absent in control mice. (D) Direct immunofluorescence
staining reveals C3c deposition in a capillary loop pattern in α3NC1immunized B6.Cfb+/+ mice. C3c staining is absent in B6.Cfb−/− mice. (E)
Indirect immunofluorescence shows C5b-9 deposition along the GBM in
α3NC1-immunized B6.Cfb+/+ mice, but not B6.Cfb−/− mice. Original
magnification 400×.

Figure 5 | Analysis of circulating anti-α3NC1 mouse IgG antibodies. The
levels of circulating mouse IgG, IgG1, IgG2b, and IgG2c antibodies binding
to rh-α3NC1 were measured by indirect ELISA. Mouse sera were diluted
1/5,000 for total IgG, 1/2,000 for IgG1, and 1/500 for IgG2b and IgG2c.
The significance of differences between Cfb−/− (KO) and Cfb+/+ (WT) mice
was evaluated by t-test (n.s., not significant).
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Figure 8 | Analysis of glomerular immune complexes and complement
deposition in D1 mice immunized with α3NC1. Kidneys were collected from
adjuvant immunized D1 mice (left), α3NC1-immunized D1.Cfb−/− mice
(middle), and α3NC1-immunized D1.Cfb−/− mice (right) at week 8 after the
initial immunization. (A) Immunofluorescence staining for mouse IgG shows
glomerular basement membrane (GBM) staining in α3NC1-immunized
D1.Cfb−/− and D1.Cfb+/+ mice. Adjuvant-immunized control mice show
non-specific mesangial IgG deposition. (B) Mean fluorescence intensity
(MFI) of IgG staining, expressed in arbitrary units (AU), was compared in
α3NC1-immunized D1.Cfb−/− and D2.Cfb+/+ mice. The difference was not
significant (n.s.) by t test. (C) Staining with mAb RH34 shows the GBM
deposition of exogenous antigen in both groups of α3NC1-immunized mice,
which is absent in control mice. (D) Direct immunofluorescence staining
reveals capillary loop deposition of C3c in α3NC1-immunized D1.Cfb+/+
mice, while C3c staining is absent in D1.Cfb−/− mice. (E) Indirect
immunofluorescence shows C5b-9 deposition along the GBM in
α3NC1-immunized D1.Cfb+/+ mice but not D1.Cfb−/− mice. Original
magnification 400×.

Figure 7 | D1.Cfb−/− mice immunized with α3NC1 are protected against
albuminuria despite developing subepithelial immune complexes. (A) Time
course of urinary albumin-to-creatinine ratio (ACR) in D1.Cfb+/+ mice (circles)
and D1.Cfb−/− mice (squares) immunized with α3NC1 (N = 7–8 per group).
Control D1 mice (triangles), including both genotypes, were immunized with
adjuvant alone (N = 5). Shown are means and SEM. (B) Scatterplot depicts
the ACR values at the last time point (week 8). The significance of differences
among groups was analyzed by one-way ANOVA with Dunnett’s correction
multiple comparisons. ***P < 0.001, ****P < 0.0001, n.s., not significant.
(C) Morphology of kidneys from α3NC1-immunized D1.Cfb−/− (left) and D1.
Cfb+/+ mice (right) appeared normal by light microscopy (periodic acid–Schiff
staining, original magnification 400×). (D) Transmission electron microscopy
shows subepithelial electron dense deposits (arrowhead), thickening of the
glomerular basement membrane (G), and podocyte (Po) foot process
effacement. Original magnification 15,000×.

greater extent than C5 deficiency under comparable experimental
conditions.

Subepithelial Immune Complexes Activate
Complement In Vitro via the AP

Since α3NC1-immunized Cfb−/− mice had glomerular IgG but
not C3c deposition, we investigated whether immune complexes
formed in these mice can activate complement in vitro. To this
end, kidney cryosections from D1.Cfb−/− mice were incubated
with normal mouse serum as a source of complement. As shown
in Figure 9, glomerular capillary loops deposition of C3c was
found after incubation with normal mouse serum in the presence
of Ca2+ and Mg2+ (in which all three pathways are active), and also
in the presence of Mg2+ and EGTA (conditions under which the

staining intensity was similar in D1.Cfb−/− and D1.Cfb+/+ mice
(Figure 8B). Staining with mAb RH34 showed GBM deposition
of exogenous antigen in these mice (Figure 8C). Capillary loop
deposition of C3c (Figure 8D) and C5b-9 staining (Figure 8E)
was observed in α3NC1-immunized D1.Cfb+/+ mice but was
absent from α3NC1 immunized D1.Cfb−/− mice. These results
confirm that the AP is essential for pathogenic complement
acti
vation by subepithelial immune complexes and further
show that the ablation of the AP abolishes proteinuria to a
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Figure 10 | Decreased glomerular basement membrane (GBM) staining
by anti-heparan sulfate mAb JM403 in experimental MN. (A) Immuno
fluorescence staining with anti-heparan sulfate mAb JM403 revealed intense
staining in the GBM of control mice, which was markedly decreased in
α3NC1-immunized B6.Cfb+/+ mice. (B) GBM staining for agrin core protein
was similar in both groups.

loss of GBM staining by anti-heparan sulfate mAb JM403, while
staining for agrin core protein was not changed. These results
demonstrate the loss of heparan sulfate epitopes from the GBM
of α3NC1-immunized mice, which may locally dysregulate the
AP by reducing the recruitment of factor H (37).
Figure 9 | In vitro complement activation by glomerular immune complexes
from α3NC1-immunized Cfb−/− mice. Immunofluorescence analysis of C3c
deposition onto kidneys cryosections from α3NC1-immunized D1.Cfb−/−
mice (left) and control non-immunized wild-type DBA/1 mice (right), after
incubation with 33% normal mouse serum in buffer containing Ca2+ and Mg2+
(A), Mg2+ and EGTA (B), or EDTA (C). Complement pathways active in each
buffer are indicated on the left, according to the key shown at the bottom.

DISCUSSION
Whereas podocyte injury by C5b-9 is a major effector mechanism
of the subepithelial immune complexes that lead to proteinuria
in MN, the role of specific complement pathways upstream of C5
activation remains poorly understood. Glomerular deposition of
complement components specific to the AP in human MN raises
the question of whether the AP activation is pathogenically
relevant or just an epiphenomenon. We addressed this question
by evaluating how the absence of a functional AP affects kidney
disease in a mouse model of MN. We found that Cfb−/− and Cfb+/+
mice immunized with α3NC1 developed subepithelial immune
complexes, with similar IgG deposition. However, Cfb−/− mice
were protected against proteinuria and did not exhibit glomerular
deposition of C3c and C5b-9. These results imply that the AP is
required for glomerular complement activation by subepithelial
immune complexes, which in turn is necessary for proteinuria.
We thus provide the first direct evidence implicating the AP in
the pathogenesis of experimental MN.
Complement activation can contribute to kidney disease at
several levels, by causing direct injury at the glomerular filtration
barrier, and also by augmenting the production of pathogenic
antibodies (38). The latter appears unlikely in our model, as the
levels of circulating anti-α3NC1 antibodies and kidney-bound
IgG were similar in Cfb−/− and wild-type mice. Hence, the more
likely mechanism by which the absence of factor B protects against
proteinuria is via the reduced complement activation at the level
of C3 and C5, as implied by the absence of glomerular C3c and
C5b-9 staining in Cfb−/− mice despite the presence of subepithelial
immune deposits. While immune complexes typically activate
complement via the classical pathway, the AP is secondarily
activated and forms an amplification loop. In a quantitative assay

alternative pathway is active, but the classical and lectin pathways
are inhibited), but not in the presence EDTA (which inhibits all
thee pathways). In control experiments using kidney cryosections from a non-immunized wild-type mouse (i.e., without
glomerular IgG deposits), no C3c deposition along the capillary
loops was observed under any conditions. Similar results were
obtained using human serum as complement source (not shown).
These results indicate that glomerular immune complexes formed
in vivo in α3NC1-immunized Cfb−/− mice have the intrinsic ability to activate complement via the AP.

The Loss of GBM Heparan Sulfate in
Experimental MN May Affect the Local
AP Regulation

Activation of the AP on extracellular matrices, which are not protected by intrinsic complement regulators, is largely controlled by
factor H. Factor H selectively inhibits the AP on host surfaces by
recognizing polyanions such as heparan sulfate as markers of self.
The normal GBM contains heparan sulfate chains attached to the
agrin core protein, but the GBM staining for heparan sulfate epitopes
is markedly decreased in human MN and rat Heymann nephritis
(34–36). We investigated whether similar changes occur after the
induction of experimental MN in mice. Compared to adjuvantimmunized control mice, α3NC1-immunized B6 (Figure 10)
and D1 mice (not shown) with proteinuria had almost complete
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of complement activation initiated via the classical pathway
(by IgM or aggregated IgG), the AP accounted for more than
80% of the C5 activation products (C5a, sC5b-9) generated in
the assay (39). This amplification explains the pathogenic role of
the AP in various animal models of immune complex-mediated
diseases, including lupus nephritis (40–42). An increased generation of C3b would exacerbate the formation of C5b-9, which is
pathogenic in MN, because C5 binding to C3b is a prerequisite
for C5 activation, and very high affinity C5 convertases only form
at high surface density of C3b (43, 44).
How glomerular immune complexes activate complement
depends on several factors, including their ultrastructural localization and immunoglobulin composition. In human anti-GBM
disease, IgG1 auto-antibodies that bind to α345(IV) collagen in
the human GBM (usually specific for α3NC1) cause severe glomerulonephritis, often featuring C3 deposition along the GBM
(45). By contrast, in wild-type mice, human or murine IgG
antibodies that bind to α345(IV) collagen in the mouse GBM are
insufficient to cause local complement activation or glomerular
injury (46, 47). It is, therefore, remarkable that subepithelial
immune complexes formed by mouse IgG anti-α3NC1 antibodies with exogenous rh-α3NC1 antigen (via a planted antigen
mechanism) are able to activate complement in vivo and in vitro,
even though anti-α3NC1 antibodies are predominantly of mouse
IgG1 subclass. Mouse IgG1 functionally resembles human IgG4
(the predominant IgG subclass in human primary MN), in that
neither binds C1q to activate the classical pathway (48). However,
mouse IgG1 can activate the AP (49), as do human IgG2 and
IgA (50). Whether human IgG4 can activate the AP remains an
important question yet to be solved. In preliminary studies, we
found that the AP amplifies in vitro complement activation by
immune complexes formed by human anti-PLA2R IgG autoantibodies (Dorin-Bogdan Borza and Laurence H. Beck, unpublished
observations).
The extent to which the AP is activated is also modulated by
the local microenvironment. Although the AP is constitutively
active and self-amplifies on foreign surfaces, its activation on
self-surfaces is normally restricted by host complement regulatory proteins that inactivate C3 and C5 convertases. In glomeruli,
podocytes are protected by membrane-bound regulators such as
CR1, while plasma factor H is recruited to inhibit the AP in the
GBM (51). Studies in the nephrotoxic nephritis model, in which
the AP contributes to chronic but not acute kidney injury, suggest
that the mechanisms controlling the AP may be impaired over
time by the persistence of antibodies or by glomerular injury (52).
One mechanism that could locally dysregulate the AP is the loss
of heparan sulfate chains, which factor H normally recognizes as
markers of self (37). Decreased GBM staining by anti-heparan
sulfate mAb JM403 occurs in α3NC1-immunized mice (this
study) and also in human MN (53) and a rat model of MN, active
Heymann nephritis (36). The loss of GBM heparan sulfate may
be the result of enzymatic cleavage by heparanase, which is often
upregulated in glomerular disease (54), including in Heymann
nephritis (55). It may also be due to other mechanisms (56). An
apparent loss of heparan sulfate occurs in lupus nephritis due to
masking by immune complexes (57). Besides factor H, heparan
sulfate can also bind properdin, thus serving as a platform for AP
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activation on some surfaces, such as the apical surface of kidney
tubules or apoptotic T cells (58, 59). In our model, given the loss
of GBM heparan sulfate, glomerular deposition of properdin is
more likely due to properdin binding to C3b and stabilization of
the C3bBb convertase (60). Elucidating the relationships among
the loss of GBM heparan sulfate, local complement regulation
and proteinuria is an area for future investigations.
The role of C5b-9 in proteinuria induced by subepithelial
immune complexes has been demonstrated in passive Heymann
nephritis (11), but not validated in other models of MN to date.
In this study, we found that C5-deficient DBA/2 mice developed
significantly less proteinuria than C5-sufficient DBA/1 mice,
which further supports the paradigm that C5 activation mediates
glomerular injury by subepithelial immune complexes. Cleavage
of C5 generates C5b, a precursor for C5b-9, and also C5a, a
pro-inflammatory anaphylatoxin. Although our results cannot
formally exclude a pathogenic role for C5a in the MN model used
in this study, there is currently no evidence to implicate C5a as
meditator of glomerular injury in MN, and inflammatory cells are
usually not detected in glomeruli in MN.
An unexpected finding in this study was that the absence of
factor B abolished proteinuria to a greater extent than the absence
of complement C5. Under similar experimental conditions,
albuminuria in C5-deficient D2 mice (ACR 2.38 ± 0.96) was
reduced by a factor of about 30 compared to C5-sufficient D1
mice (ACR 77.1 ± 20.8), while albuminuria in D1.Cfb−/− mice
(ACR 0.36 ± 0.12) was reduced by a factor of about 200 compared
to D1.Cfb+/+ mice (ACR 78.8 ± 18.1)—a sixfold difference. This
difference may be explained by the fact the absence of C5 only
prevents events downstream of C5 activation (such as C5b-9 formation), while the absence of factor B also inhibits complement
activation at the level of C3. Indeed, glomerular C3c deposition
was absent in Cfb−/− mice but present in C5-null mice. These
results suggest that complement activation at the level of C3 may
also contribute to proteinuria in MN, independently of C5b-9mediated glomerular injury.
Our study has some limitations. The role of the AP in experimental MN was only investigated using genetic approaches.
Further corroboration by pharmacologic inhibition of the AP in
a clinically relevant setting is desirable. This is evaluated in ongoing studies. Another potential caveat is that subepithelial immune
complexes induced by immunization with α3NC1 are formed
by a planted antigen mechanism, recapitulating secondary MN
rather than primary MN. Nonetheless, glomerular deposition of
factor B occurs not only in primary but also secondary MN (6),
suggesting that the AP is involved regardless of how subepithelial
immune complexes form. We expect that future studies will
address the pathogenic role of the AP in emerging animal models
of MN, which target autoantigens implicated in human disease. Of
interest in this regard, mice injected with human anti-THSD7A
antibodies develop mild proteinuria with histologic features of
MN (61). However, efforts to develop models of MN targeting
PLA2R have been hampered by the fact that rodents (unlike
humans) do not express PLA2R on podocytes.
A better understanding of the complement-mediated mechanisms of injury in MN may help develop novel therapies for
MN. MN is a common cause of nephrotic syndrome in adults,
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and up to 40% of patients eventually develop end-stage renal
disease (62). Current therapies use non-specific immunosuppressive drugs, which have significant toxic side effects and are
ineffective in about 25–30% of patients (2, 63, 64). Therapeutic
inhibition of complement may be a viable approach for treating
MN (65), especially in patients who do not respond to conventional therapy or have rapid deterioration of renal function. One
anti-complement agent already in clinical use is eculizumab,
a humanized IgG2/IgG4 anti-C5 monoclonal antibody that
blocks C5 activation. An early, unpublished clinical trial of
eculizumab in primary MN did not find a significant remission of proteinuria after 16 weeks of treatment, which may be
explained by the insufficient dosage of the drug. Indeed, a recent
study has found that C5 inhibition by eculizumab is incomplete
at high C3b density (44), a setting relevant to MN. Compared
to eculizumab, which does not prevent potentially harmful C3
activation, agents that inhibit complement at the level of both
C3 and C5 may offer additional therapeutic benefit. The results
of this study identify the AP as a novel target for therapy in MN.
Inhibition of the AP has the advantage of leaving the classical
and lectin pathways intact for defense against pathogens and
other homeostatic functions.
In summary, our results suggest that the AP is necessary
for sustained complement activation by subepithelial immune
complexes, leading to glomerular deposition of C3c and C5b-9.
Furthermore, the activation of the AP is essential for the development of proteinuria in experimental MN. These findings may
provide a framework for the rational design of new therapies for
MN.
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